FULCRUM THERAPEUTICS INC (FULC) Stock News

USA - NASDAQ:FULC - US3596161097 - Common Stock

7.07 USD

+0.07 (+1%)

Last: 9/15/2025, 8:00:01 PM

7.07 USD

0 (0%)

After Hours: 9/15/2025, 8:00:01 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

FULC Latest News, Press Relases and Analysis

All

Press Releases

3 days ago - By: Fulcrum Therapeutics, Inc.

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

3 days ago - By: Fulcrum Therapeutics, Inc.

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

21 days ago - By: Fulcrum Therapeutics, Inc.

Fulcrum Therapeutics to Present at Upcoming Investor Meetings

21 days ago - By: Fulcrum Therapeutics, Inc.

Fulcrum Therapeutics to Present at Upcoming Investor Meetings

a month ago - By: Fulcrum Therapeutics, Inc.

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

a month ago - By: Fulcrum Therapeutics, Inc.

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

2 months ago - By: Benzinga - Mentions: STX CAR EDU TAL ...

Avis Budget Group Posts Downbeat Earnings, Joins SoFi Technologies, Seagate And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

2 months ago - By: Benzinga - Mentions: EXEL HLIT VRSN NVO ...

Whirlpool Posts Downbeat Earnings, Joins Harmonic, Stanley Black & Decker And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

2 months ago - By: Fulcrum Therapeutics, Inc.

Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Second Quarter 2025

2 months ago - By: Fulcrum Therapeutics, Inc.

Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Second Quarter 2025

2 months ago - By: Fulcrum Therapeutics, Inc.

Fulcrum Therapeutics Announces Results from the 12 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease

2 months ago - By: Fulcrum Therapeutics, Inc.

Fulcrum Therapeutics Announces Results from the 12 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease

2 months ago - By: Fulcrum Therapeutics, Inc.

Fulcrum Therapeutics to Present Results from the 12 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease

2 months ago - By: Fulcrum Therapeutics, Inc.

Fulcrum Therapeutics to Present Results from the 12 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease

2 months ago - By: Fulcrum Therapeutics, Inc.

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

2 months ago - By: Fulcrum Therapeutics, Inc.

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

3 months ago - By: Fulcrum Therapeutics, Inc.

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

3 months ago - By: Fulcrum Therapeutics, Inc.

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

4 months ago - By: Fulcrum Therapeutics, Inc.

Fulcrum Therapeutics to Present at Upcoming Medical Meetings

4 months ago - By: Fulcrum Therapeutics, Inc.

Fulcrum Therapeutics to Present at Upcoming Medical Meetings

4 months ago - By: Fulcrum Therapeutics, Inc.

Fulcrum Therapeutics to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference

4 months ago - By: Fulcrum Therapeutics, Inc.

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

4 months ago - By: Fulcrum Therapeutics, Inc.

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

4 months ago - By: Fulcrum Therapeutics, Inc.

Fulcrum Therapeutics to Participate in Upcoming May Conferences

5 months ago - By: Fulcrum Therapeutics, Inc.

Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 2025

5 months ago - By: Fulcrum Therapeutics, Inc.

Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 2025

5 months ago - By: Fulcrum Therapeutics, Inc.

Fulcrum Therapeutics to Host First Quarter 2025 Financial Results Conference Call and Webcast on Thursday, May 1, 2025, at 8:00 a.m. ET

5 months ago - By: Fulcrum Therapeutics, Inc.

Fulcrum Therapeutics to Host First Quarter 2025 Financial Results Conference Call and Webcast on Thursday, May 1, 2025, at 8:00 a.m. ET